EA018700B1 - МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ И ИХ ПРИМЕНЕНИЕ - Google Patents

МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ И ИХ ПРИМЕНЕНИЕ Download PDF

Info

Publication number
EA018700B1
EA018700B1 EA200970515A EA200970515A EA018700B1 EA 018700 B1 EA018700 B1 EA 018700B1 EA 200970515 A EA200970515 A EA 200970515A EA 200970515 A EA200970515 A EA 200970515A EA 018700 B1 EA018700 B1 EA 018700B1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
ece
cancer
modified fusion
rgo
Prior art date
Application number
EA200970515A
Other languages
English (en)
Russian (ru)
Other versions
EA200970515A1 (ru
Inventor
Марк Несбит
Беатрис Камерон
Франсис БЛАНШ
Сильви Сорделло
Селин Николацци
Марк Тромб
Original Assignee
Авентис Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA018700(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Авентис Фарма С.А. filed Critical Авентис Фарма С.А.
Publication of EA200970515A1 publication Critical patent/EA200970515A1/ru
Publication of EA018700B1 publication Critical patent/EA018700B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA200970515A 2006-11-28 2007-11-28 МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ И ИХ ПРИМЕНЕНИЕ EA018700B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11
PCT/IB2007/004354 WO2008065543A2 (en) 2006-11-28 2007-11-28 Modified soluble fgf receptor fc fusions with improved biological activity

Publications (2)

Publication Number Publication Date
EA200970515A1 EA200970515A1 (ru) 2009-12-30
EA018700B1 true EA018700B1 (ru) 2013-10-30

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970515A EA018700B1 (ru) 2006-11-28 2007-11-28 МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ И ИХ ПРИМЕНЕНИЕ

Country Status (33)

Country Link
US (3) US8119770B2 (OSRAM)
EP (1) EP2092069B2 (OSRAM)
JP (1) JP2010510801A (OSRAM)
KR (1) KR20090102769A (OSRAM)
AR (1) AR063975A1 (OSRAM)
AT (1) ATE509106T1 (OSRAM)
AU (1) AU2007326985C1 (OSRAM)
BR (1) BRPI0719290A2 (OSRAM)
CA (1) CA2668932A1 (OSRAM)
CL (1) CL2007003411A1 (OSRAM)
CO (1) CO6190564A2 (OSRAM)
CR (1) CR10777A (OSRAM)
CY (1) CY1112435T1 (OSRAM)
DK (1) DK2092069T3 (OSRAM)
EA (1) EA018700B1 (OSRAM)
EC (1) ECSP099361A (OSRAM)
GT (1) GT200900137A (OSRAM)
HR (1) HRP20110503T1 (OSRAM)
IL (1) IL198480A0 (OSRAM)
MA (1) MA31143B1 (OSRAM)
MX (1) MX2009005692A (OSRAM)
MY (1) MY145914A (OSRAM)
NI (1) NI200900097A (OSRAM)
NO (1) NO20092414L (OSRAM)
PE (1) PE20081250A1 (OSRAM)
PL (1) PL2092069T3 (OSRAM)
PT (1) PT2092069E (OSRAM)
RS (1) RS51911B (OSRAM)
SI (1) SI2092069T1 (OSRAM)
SV (1) SV2009003272A (OSRAM)
TN (1) TN2009000184A1 (OSRAM)
TW (1) TW200839012A (OSRAM)
WO (1) WO2008065543A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2794170C2 (ru) * 2017-09-20 2023-04-12 Пфайзер Инк. ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3)
US11814654B2 (en) 2013-01-16 2023-11-14 Institut National De La Sante Et De La Recherche Medicale Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
PL2498799T3 (pl) 2009-11-13 2017-03-31 Five Prime Therapeutics, Inc. Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
CN107050426A (zh) * 2010-11-15 2017-08-18 戊瑞治疗有限公司 Fgfr1胞外域组合疗法
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2655408B1 (en) 2010-12-23 2016-07-06 Sanofi Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US10016484B2 (en) * 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
AU2014249224B2 (en) 2013-03-11 2019-01-17 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
WO2014190147A2 (en) * 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
PH12019501393B1 (en) 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN108368174B (zh) * 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
BR112019023898A2 (pt) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição
JP6967578B2 (ja) 2017-11-30 2021-11-17 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 免疫チェックポイント阻害剤ｐｄ−１及びｐｄ−ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
US12448415B2 (en) * 2018-01-04 2025-10-21 Washington University Compositions and methods for inhibition of alphavirus infection
MX2020007018A (es) * 2018-01-26 2020-09-07 Genentech Inc Proteinas de fusion fc il-22 y metodos de uso.
AU2020253455A1 (en) 2019-04-03 2021-11-04 Genzyme Corporation Anti-alpha beta TCR binding polypeptides with reduced fragmentation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
DK0481000T3 (da) 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
WO1991017183A1 (en) * 1990-04-27 1991-11-14 Takeda Chemical Industries, Ltd. Proteins with fibroblast growth factor receptor activity
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
AU662107B2 (en) 1990-07-06 1995-08-24 Aventis Pharmaceuticals Inc. Fibroblast growth factor receptors
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
CA2412882A1 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
EP1331266B1 (en) * 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
JPWO2003085118A1 (ja) * 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
KR100980065B1 (ko) * 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
JP2007525187A (ja) 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
AU2004280066A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
EP2940043A1 (en) 2004-07-15 2015-11-04 Xencor, Inc. Optimized fc variants
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDERSON JANE ET AL.: "Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand", HUMAN MOLECULAR GENETICS, vol. 7, no. 9, September 1998 (1998-09), pages 1475-1483, XP002429673, ISSN: 0964-6906, page 1480, 1481 *
DUCHESNE LAURENCE ET AL.: "N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 37, September 2006 (2006-09), pages 27178-27189, XP002429674, ISSN: 0021-9258, abstract; fig. 2 *
POWELL ANDREW K. ET AL.: "Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. Implications for dynamic assembly of a ternary signaling complex", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 32, 9 August 2002 (2002-08-09), pages 28554-28563, XP002429672, ISSN: 0021-9258, the whole document *
TRUEB BEAT ET AL.: "Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 36, 5 September 2003 (2003-09-05), pages 33857-33865, XP002429675, ISSN: 0021-9258 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814654B2 (en) 2013-01-16 2023-11-14 Institut National De La Sante Et De La Recherche Medicale Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
RU2794170C2 (ru) * 2017-09-20 2023-04-12 Пфайзер Инк. ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3)

Also Published As

Publication number Publication date
PE20081250A1 (es) 2008-10-07
AU2007326985A1 (en) 2008-06-05
IL198480A0 (en) 2011-08-01
AR063975A1 (es) 2009-03-04
EP2092069B2 (en) 2013-12-18
US8119770B2 (en) 2012-02-21
GT200900137A (es) 2011-09-02
PT2092069E (pt) 2011-07-29
US8481487B2 (en) 2013-07-09
MA31143B1 (fr) 2010-02-01
ECSP099361A (es) 2009-06-30
DK2092069T3 (da) 2011-08-29
CY1112435T1 (el) 2015-12-09
SV2009003272A (es) 2010-02-05
NI200900097A (es) 2010-01-26
CR10777A (es) 2009-07-23
HRP20110503T1 (hr) 2011-08-31
EP2092069A2 (en) 2009-08-26
SI2092069T1 (sl) 2011-09-30
EP2092069B1 (en) 2011-05-11
AU2007326985B2 (en) 2013-08-15
EA200970515A1 (ru) 2009-12-30
MX2009005692A (es) 2009-10-12
ATE509106T1 (de) 2011-05-15
RS51911B (sr) 2012-02-29
PL2092069T3 (pl) 2011-10-31
CA2668932A1 (en) 2008-06-05
JP2010510801A (ja) 2010-04-08
CL2007003411A1 (es) 2008-07-04
MY145914A (en) 2012-05-15
AU2007326985C1 (en) 2014-02-20
TW200839012A (en) 2008-10-01
BRPI0719290A2 (pt) 2014-02-25
WO2008065543A2 (en) 2008-06-05
US20100061979A1 (en) 2010-03-11
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
KR20090102769A (ko) 2009-09-30
NO20092414L (no) 2009-08-21
CO6190564A2 (es) 2010-08-19
WO2008065543A3 (en) 2008-08-14
US20120195851A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
EA018700B1 (ru) МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ И ИХ ПРИМЕНЕНИЕ
JP7201725B2 (ja) 治療用ｒｎａ
EA019595B1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
CN105121474B (zh) 融合免疫调节蛋白及其制备方法
Wu et al. Chemokine receptors as targets for cancer therapy
Spangler et al. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression
CN113527495A (zh) 与cd38结合的抗体治疗剂
US10874724B2 (en) Enzymatic immunomodulation of solid tumors and uses thereof
EA018717B1 (ru) Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение
US12103954B2 (en) Heterodimeric Fc cytokines and uses thereof
EP4201424A1 (en) Antitumor agent and antitumor effect enhancer
JP7744990B2 (ja) 抗ｐｄ－ｌ１／抗４－１ｂｂ天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法
EP3007773B1 (en) Ige antibodies for the inhibition of tumor metastasis
CN101589145B (zh) 经修饰的具有改良生物活性的可溶性FGF受体Fc融合物
US20240034803A1 (en) Anti-cd39 antibodies and use thereof
TW201625301A (zh) 藉由ｆｏｌｒ１標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥
HK1212920A1 (zh) 使用麦胶蛋白肽治疗癌症的套件和方法
EP4455162A1 (en) Fusion proteins composed of an antibody and a mutein
Rau Dual-and triple-targeting of the HER-family members using combinations of mono-and bispecific antibodies
WO2025078686A1 (en) Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer
HK1139177A (en) Modified soluble fgf receptor fc fusions with improved biological activity
HK1217343B (zh) 融合免疫调节蛋白及其制备方法

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU